[go: up one dir, main page]

WO2005110360A3 - Compositions pour injection - Google Patents

Compositions pour injection Download PDF

Info

Publication number
WO2005110360A3
WO2005110360A3 PCT/EP2005/005365 EP2005005365W WO2005110360A3 WO 2005110360 A3 WO2005110360 A3 WO 2005110360A3 EP 2005005365 W EP2005005365 W EP 2005005365W WO 2005110360 A3 WO2005110360 A3 WO 2005110360A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
injection
composition
intramuscular
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/005365
Other languages
English (en)
Other versions
WO2005110360A2 (fr
Inventor
Steve Leigh
Mathew Louis Steven Leigh
Hoogevest Peter Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phares Pharmaceutical Research NV
Original Assignee
Phares Pharmaceutical Research NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phares Pharmaceutical Research NV filed Critical Phares Pharmaceutical Research NV
Publication of WO2005110360A2 publication Critical patent/WO2005110360A2/fr
Publication of WO2005110360A3 publication Critical patent/WO2005110360A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique homogène destinée à la libération progressive de composés biologiquement actifs après une administration intramusculaire ou sous-cutanée, et renfermant au moins un lipide membranaire sous forme cristalline liquide. L'invention concerne également un procédé de préparation de cette composition.
PCT/EP2005/005365 2004-05-18 2005-05-17 Compositions pour injection Ceased WO2005110360A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04252942 2004-05-18
EP04252942.0 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005110360A2 WO2005110360A2 (fr) 2005-11-24
WO2005110360A3 true WO2005110360A3 (fr) 2006-04-06

Family

ID=35394648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005365 Ceased WO2005110360A2 (fr) 2004-05-18 2005-05-17 Compositions pour injection

Country Status (1)

Country Link
WO (1) WO2005110360A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
IL296882A (en) 2012-07-26 2022-12-01 Camurus Ab Opioid formulations
EP2877155B1 (fr) 2012-07-26 2020-10-28 Camurus AB Formulations d'opioïdes
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004611A (en) * 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
EP0648494A1 (fr) * 1993-09-30 1995-04-19 American Home Products Corporation Formulations de rapamycine pour l'administration orale
US6599527B1 (en) * 1997-06-20 2003-07-29 Phares Pharmaceutical Research N.V. Preparation of pharmaceutical compositions
US6605298B1 (en) * 1998-03-05 2003-08-12 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004611A (en) * 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
EP0648494A1 (fr) * 1993-09-30 1995-04-19 American Home Products Corporation Formulations de rapamycine pour l'administration orale
US6599527B1 (en) * 1997-06-20 2003-07-29 Phares Pharmaceutical Research N.V. Preparation of pharmaceutical compositions
US6605298B1 (en) * 1998-03-05 2003-08-12 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURTHA J L ET AL: "SYNTHESIS OF THE CHOLESTERYL ESTER PRODRUGS CHOLESTERYL IBUPROFEN AND CHOLESTERYL FLUFENAMATE AND THEIR FORMULATION INTO PHOSPHOLIPID MICROEMULSIONS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 83, no. 9, 1 September 1994 (1994-09-01), pages 1222 - 1228, XP000465804, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2005110360A2 (fr) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2008041245A3 (fr) Nouvelles compositions en dépôt injectables et leur procédé de fabrication
WO2007084460A8 (fr) Compositions pharmaceutiques a stabilite amelioree
EP2422798A3 (fr) Compositions comprenant des cellules souches embryonnaires humaines et leurs dérivés, procédés d'utilisation et procédés de préparation
UA95828C2 (ru) Твердая рецептура, которая содержит алоглиптин и пиоглитазон
WO2006017852A3 (fr) Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs
WO2001087284A3 (fr) Composition antagoniste de l'aldosterone destinee a etre liberee durant l'acrophase de l'aldosterone
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
WO2010041141A3 (fr) Support expansible à base d’huile et préparations
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
WO2008063910A3 (fr) Procédé pour préparer des formes de dosage solides de compositions pharmaceutiques à plusieurs phases
WO2007103200A3 (fr) Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
WO2008039415A3 (fr) Analogues de ghréline substitués au niveau du n-terminal
WO2006065951A3 (fr) Preparation a liberation continue de composes d'octreotide
WO2008107149A3 (fr) Forme pharmaceutique rendant l'usage abusif plus difficile
WO2007047948A3 (fr) Administration intranasale d'insuline a action rapide
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2008065097A3 (fr) Composition pharmaceutique solide stabilisee de candesartan cilexetil
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2008075320A3 (fr) Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
WO2008070141A3 (fr) Compositions pour administrer des agents thérapeutiques
WO2005110360A3 (fr) Compositions pour injection
WO2008001204A3 (fr) Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase